Doctors and researchers have striven to find a “troponin-equivalent” marker for the precise identification of patients with AKI at an early stage, such as cystatin C, kidney injury molecule-1, or neutrophil gelatinase-associated lipocalin [49,50,51]. This evidence concerns the gene LCN2 and acute kidney injury.